Literature DB >> 26804815

Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System.

Vivien J Coulson-Thomas1, Yvette M Coulson-Thomas2, Tarsis F Gesteira3, Winston W-Y Kao4.   

Abstract

Mesenchymal stem cells (MSCs) are a group of fibroblast-like multipotent mesenchymal stromal cells that have the ability to differentiate into osteoblasts, adipocytes, and chondrocytes. Recent studies have demonstrated that MSCs possess a unique ability to exert suppressive and regulatory effects on both adaptive and innate immunity in an autologous and allogeneic manner. A vital step in stem cell transplantation is overcoming the potential graft-versus-host disease, which is a limiting factor to transplantation success. Given that MSCs attain powerful differentiation capabilities and also present immunosuppressive properties, which enable them to survive host immune rejection, MSCs are of great interest. Due to their ability to differentiate into different cell types and to suppress and modulate the immune system, MSCs are being developed for treating a plethora of diseases, including immune disorders. Moreover, in recent years, MSCs have been genetically engineered to treat and sometimes even cure some diseases, and the use of MSCs for cell therapy presents new perspectives for overcoming tissue rejection. In this review, we discuss the potential extrinsic and intrinsic mechanisms that underlie MSCs' unique ability to modulate inflammation, and both innate and adaptive immunity.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  graft versus host disease; immunity; inflammation; mesenchymal stem cells; stem cell transplantation

Mesh:

Year:  2016        PMID: 26804815      PMCID: PMC4842329          DOI: 10.1016/j.jtos.2015.11.004

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  198 in total

1.  CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion.

Authors:  Noriyuki Kijima; Naoki Hosen; Naoki Kagawa; Naoya Hashimoto; Akiko Nakano; Yasunori Fujimoto; Manabu Kinoshita; Haruo Sugiyama; Toshiki Yoshimine
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp.

Authors:  Laura Pierdomenico; Laura Bonsi; Mario Calvitti; Damiano Rondelli; Mario Arpinati; Gabriella Chirumbolo; Ennio Becchetti; Cosetta Marchionni; Francesco Alviano; Valentina Fossati; Nicola Staffolani; Michele Franchina; Alberto Grossi; Gian Paolo Bagnara
Journal:  Transplantation       Date:  2005-09-27       Impact factor: 4.939

3.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

Review 4.  Stem cell-based therapies for age-related macular degeneration: current status and prospects.

Authors:  Yalin Mu; Manli Zhao; Guangming Su
Journal:  Int J Clin Exp Med       Date:  2014-11-15

5.  Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion.

Authors:  Xuebin Qu; Xingxia Liu; Kai Cheng; Rongcun Yang; Robert C H Zhao
Journal:  Exp Hematol       Date:  2012-05-23       Impact factor: 3.084

6.  Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC).

Authors:  B Homey; W Wang; H Soto; M E Buchanan; A Wiesenborn; D Catron; A Müller; T K McClanahan; M C Dieu-Nosjean; R Orozco; T Ruzicka; P Lehmann; E Oldham; A Zlotnik
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

7.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

8.  Mesenchymal stem/progenitor cells in human umbilical cord blood as support for ex vivo expansion of CD34(+) hematopoietic stem cells and for chondrogenic differentiation.

Authors:  Jin-Fu Wang; Li-Juan Wang; Yi-Fan Wu; Ying Xiang; Chun-Gang Xie; Bing-Bing Jia; Jenny Harrington; Ian K McNiece
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

9.  Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid: inter-alpha-trypsin inhibitor is crucial to structure and function.

Authors:  Carol A de la Motte; Vincent C Hascall; Judith Drazba; Sudip K Bandyopadhyay; Scott A Strong
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

10.  Kinetics and function of mesenchymal stem cells in corneal injury.

Authors:  Yinan Lan; Shilpa Kodati; Hyun Soo Lee; Masahiro Omoto; Yiping Jin; Sunil K Chauhan
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-14       Impact factor: 4.799

View more
  28 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 2.  Cell Therapy of Corneal Diseases.

Authors:  Winston W-Y Kao; Vivien J Coulson-Thomas
Journal:  Cornea       Date:  2016-11       Impact factor: 2.651

3.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

4.  New ex vivo model of corneal endothelial phacoemulsification injury and rescue therapy with mesenchymal stromal cell secretome.

Authors:  Majid Rouhbakhshzaeri; Behnam Rabiee; Nathalie Azar; Elham Ghahari; Ilham Putra; Medi Eslani; Ali R Djalilian
Journal:  J Cataract Refract Surg       Date:  2018-12-07       Impact factor: 3.351

Review 5.  Pleiotropic roles of autophagy in stem cell-based therapies.

Authors:  Vladimir Beljanski; Karl-Henrik Grinnemo; Cecilia Österholm
Journal:  Cytotherapy       Date:  2019-03-12       Impact factor: 5.414

6.  Curcumin preconditioning enhances the efficacy of adipose-derived mesenchymal stem cells to accelerate healing of burn wounds.

Authors:  Maryam Azam; Hafiz Ghufran; Hira Butt; Azra Mehmood; Ramla Ashfaq; Asad M Ilyas; Muhammad R Ahmad; Sheikh Riazuddin
Journal:  Burns Trauma       Date:  2021-09-11

Review 7.  Chasing the recipe for a pro-regenerative immune system.

Authors:  James W Godwin; Alexander R Pinto; Nadia A Rosenthal
Journal:  Semin Cell Dev Biol       Date:  2016-08-10       Impact factor: 7.727

Review 8.  The Role of Stem Cells in the Treatment of Cerebral Palsy: a Review.

Authors:  Anahita Kiasatdolatabadi; Nasrin Lotfibakhshaiesh; Meysam Yazdankhah; Somayeh Ebrahimi-Barough; Mina Jafarabadi; Arman Ai; Esmaeil Sadroddiny; Jafar Ai
Journal:  Mol Neurobiol       Date:  2016-08-13       Impact factor: 5.590

9.  Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function.

Authors:  Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Asha Tadepalli; Khandaker N Anwar; John A Kink; Samaneh Ghassemi; Gaurav Agnihotri; Sofiya Reshetylo; Alireza Mashaghi; Reza Dana; Peiman Hematti; Ali R Djalilian
Journal:  Stem Cells       Date:  2018-01-27       Impact factor: 6.277

10.  Emerging Approaches for Ocular Surface Regeneration.

Authors:  Ghasem Yazdanpanah; Sayena Jabbehdari; Ali R Djalilian
Journal:  Curr Ophthalmol Rep       Date:  2019-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.